Post launch studies
Launching a product in Pharma or Biotech marks the beginning of a new phase of evidence generation and commercial validation. Post launch, organisations must understand how their innovation performs in real-world environments, how it is adopted across stakeholder segments, and where refinement may enhance uptake or long-term value.
Our Post Launch Studies provide structured, evidence-driven insight to evaluate real-world performance, stakeholder experience and adoption behaviour – supporting strategic decisions that maximise impact beyond launch.
The role of post launch studies in Pharma & Biotech
Post launch studies serve multiple strategic purposes:
- Measure real-world utilisation and clinical impact
- Validate value claims with targeted evidence
- Identify barriers to adoption or behavioural friction
- Inform iterative optimisation of messaging, positioning and evidence strategy
- Support reimbursement narratives and stakeholder engagement
Rather than relying solely on pre-launch assumptions, organisations benefit from structured post-launch insight that reflects how products are perceived and used in practice.
Our post launch approach
Drawing on both qualitative and quantitative methodologies, we design studies that generate actionable evidence across key dimensions of product performance and stakeholder experience.
Stakeholder-centred evaluation
Post launch insight must reflect how different stakeholder groups – clinicians, payers, patients and health system leaders – interact with the product in real contexts. We capture nuanced feedback on utility, decision drivers and perceived value that can reveal mismatches between expectation and reality.
Real-world usage patterns
Quantitative studies analyse adoption patterns, utilisation frequency, treatment pathways and segment differences to understand how the product fits into diverse clinical, operational and economic environments.
Barriers and enablers of adoption
Even scientifically robust products may encounter adoption friction. We identify systemic, behavioural and contextual barriers – and equally, the enablers that accelerate uptake – providing insight to refine go-to-market strategies and stakeholder engagement approaches.
Value confirmation and messaging refinement
Post launch evidence allows you to confirm, refine or reposition value claims with empirical backing. This is particularly important when engaging payers, regulators or institutional buyers who demand robust proof of impact.
Application across Pharma & Biotech segments
Our Post Launch Studies are tailored to the unique needs of different product types within the pharmaceutical and biotechnology ecosystem:
- Small molecules and biotherapeutics
For traditional therapeutic products, post launch studies explore real-world safety and efficacy perceptions, usage patterns and payer feedback – supporting sustainable adoption and pricing strategies. - Advanced therapies
In complex modalities such as cell and gene therapies, post launch evidence is critical to validate long-term performance and build confidence among clinicians and healthcare systems. - Companion diagnostics
Post launch insight reveals how diagnostic tools are integrated into treatment pathways, informing evidence strategies that support broader clinical utilization and reimbursement narratives. - Platform technologies and enabling solutions
For enabling platforms, studies focus on real-world workflow integration, user feedback and segment-specific uptake to support both commercial planning and iterative development.
What post launch studies deliver
Evidence that matters
Robust, contextually relevant evidence supports product credibility, stakeholder confidence and long-term commercial success.
Adoption insight
Understanding real-world uptake patterns enables more effective targeting, messaging refinement and commercial planning.
Strategic adaptation
Insights identify where adjustments – in positioning, messaging or evidence strategy – can enhance product performance and stakeholder resonance.
Organisational alignment
Post launch evidence serves as a common reference for R&D, medical affairs, regulatory and commercial teams, aligning strategy with observed outcomes.
Link to Case Studies and Capabilities
Our case studies demonstrate how post launch insight has informed strategic decisions in real Pharma & Biotech contexts – from optimising stakeholder engagement and refining value narratives to supporting payer conversations and portfolio adaptation.
Post launch evaluation is a core element of our broader Capabilities, connecting with positioning, opportunity assessment, pricing strategy and product definition to support continuous, evidence-based decision frameworks.
Engage with our post launch experts
If your organisation is seeking to understand real-world performance, validate value narratives or refine stakeholder engagement approaches post launch, our specialists provide evidence-based insight and strategic guidance to support sustained impact and long-term success.